Abstract:Rejection of solid organ transplant and graft versus host disease (GvHD) continue to be challenging in post transplantation management. The introduction of calcineurin inhibitors dramatically improved recipients' short-term prognosis. However, long-term clinical outlook remains poor, moreover, the lifelong dependency on these toxic drugs leads to chronic deterioration of graft function, in particular the renal function, infections and de-novo malignancies. These observations led investigators to identify alternative therapeutic options to promote long-term graft survival, which could be used concomitantly, but preferably, replace pharmacologic immunosuppression as standard of care. Adoptive T cell (ATC) therapy has evolved as one of the most promising approaches in regenerative medicine in the recent years. A range of cell types with disparate immunoregulatory and regenerative properties are actively being investigated as potential therapeutic agents for specific transplant rejection, autoimmunity or injury-related indications. A significant body of data from preclinical models pointed to efficacy of cellular therapies. Significantly, early clinical trial observations have confirmed safety and tolerability, and yielded promising data in support of efficacy of the cellular therapeutics. The first class of these therapeutic agents commonly referred to as advanced therapy medicinal products have been approved and are now available for clinical use. Specifically, clinical trials have supported the utility of CD4 + CD25+FOXP3+ regulatory T cells (Tregs) to minimize unwanted or overshooting immune responses and reduce the level of pharmacological immunosuppression in transplant recipients. Tregs are recognized as the principal orchestrators of maintaining peripheral tolerance, thereby blocking excessive immune responses and prevent autoimmunity. Here, we summarize rationale for the adoptive Treg therapy, challenges in manufacturing and clinical experiences with this novel living drug and outline future perspectives of its use in transplantation.

Conferring alloantigen specificity to regulatory T cells: A comparative analysis of cell preparations undergoing clinical development in transplantation

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

Gut Microbes Enlarged the Protective Effect of Transplanted Regulatory B Cells on Rejection of Cardiac Allografts.

Ex Vivo Expansion of Human Tregs Specific for Alloantigens Presented Directly or Indirectly.

Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance

T regulatory cells as an immunotherapy for transplantation.

Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity

T Regulatory Cells As an Immunotherapy for Transplantation

Antigen-Dependent Suppression of Alloresponses by Foxp3-Induced Regulatory T Cells in Transplantation

Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation

Induced Regulatory T Cells as Immunotherapy in Allotransplantation and Autoimmunity: Challenges and Opportunities

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective

The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology

Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance

CAR Treg synergy with anti-CD154 mediates infectious tolerance to dictate heart transplant outcomes.

Therapy with regulatory T-cell infusion in autoimmune diseases and organ transplantation: A review of the strengths and limitations

Chimeric antigen receptor Treg therapy in transplantation

Current status and perspectives of regulatory T cell-based therapy

Graft-Specific Regulatory T Cells for Long-Lasting, Local Tolerance Induction

Efficient Generation of Human Alloantigen-Specific CD4+ Regulatory T Cells from Naive Precursors by CD40-activated B Cells

Tregs in transplantation tolerance: role and therapeutic potential